These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia. Kolovou G; Diakoumakou O; Kolovou V; Fountas E; Stratakis S; Zacharis E; Liberopoulos EN; Matsouka F; Tsoutsinos A; Mastorakou I; Katsikas T; Mavrogeni S; Hatzigeorgiou G Eur J Prev Cardiol; 2020 Jan; 27(2):157-165. PubMed ID: 31403880 [TBL] [Abstract][Full Text] [Related]
6. Two new drugs for homozygous familial hyperchelesterolemia. Med Lett Drugs Ther; 2013 Apr; 55(1413):25-7. PubMed ID: 23545581 [No Abstract] [Full Text] [Related]
8. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia. Gouni-Berthold I; Berthold HK Atheroscler Suppl; 2015 May; 18():28-34. PubMed ID: 25936301 [TBL] [Abstract][Full Text] [Related]
9. Familial hypercholesterolaemia: new treatment options. Ezzahti M; Sijbrands EJ; Mulder MT; Roeters van Lennep JE Neth J Med; 2013 Jun; 71(5):227-33. PubMed ID: 23799308 [TBL] [Abstract][Full Text] [Related]
11. Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia. Blom DJ; Averna MR; Meagher EA; du Toit Theron H; Sirtori CR; Hegele RA; Shah PK; Gaudet D; Stefanutti C; Vigna GB; Larrey D; Bloedon LT; Foulds P; Rader DJ; Cuchel M Circulation; 2017 Jul; 136(3):332-335. PubMed ID: 28716835 [No Abstract] [Full Text] [Related]
12. Pharmacogenetics in the Development of Lipid Lowering Medications: Lomitapide & Mipomersen in Clinical Practice. Marbach JA; Thapa J; Goldenberg E; Duffy D Del Med J; 2015 Aug; 87(8):238-43. PubMed ID: 26402926 [TBL] [Abstract][Full Text] [Related]
13. Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia. Won JI; Zhang J; Tecson KM; McCullough PA Rev Cardiovasc Med; 2017; 18(1):21-28. PubMed ID: 28509890 [TBL] [Abstract][Full Text] [Related]
14. For patients who inherit homozygous familial hypercholesterolemia, 2 new treatments available. Morrow T Manag Care; 2013 Mar; 22(3):47-8. PubMed ID: 23610808 [No Abstract] [Full Text] [Related]
15. Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia. Cuchel M; Blom DJ; Averna MR Atheroscler Suppl; 2014 Sep; 15(2):33-45. PubMed ID: 25257075 [TBL] [Abstract][Full Text] [Related]
16. Lipid-lowering treatment for homozygous familial hypercholesterolaemia--authors' reply. Cuchel M; Rader DJ Lancet; 2013 Apr; 381(9873):1183. PubMed ID: 23561998 [No Abstract] [Full Text] [Related]
18. Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia. Raper A; Kolansky DM; Sachais BS; Meagher EA; Baer AL; Cuchel M J Clin Lipidol; 2015; 9(1):107-12. PubMed ID: 25670368 [TBL] [Abstract][Full Text] [Related]
19. The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations. Agarwala A; Jones P; Nambi V Curr Atheroscler Rep; 2015 Jan; 17(1):467. PubMed ID: 25398643 [TBL] [Abstract][Full Text] [Related]
20. Novel therapies for treating familial hypercholesterolemia. Bandeali SJ; Daye J; Virani SS Curr Atheroscler Rep; 2014 Jan; 16(1):382. PubMed ID: 24293346 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]